Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease

Alzheimer's & dementia : the journal of the Alzheimer's Association

Alzheimers Dement. 2017 Nov;13(11):1251-1260. doi: 10.1016/j.jalz.2017.03.007. Epub 2017 Apr 29.


INTRODUCTION: We aimed to investigate if cerebral amyloid angiopathy (CAA) is more frequent in genetically determined than in sporadic early-onset forms of Alzheimer's disease (AD) (early-onset AD [EOAD]).

METHODS: Neuroimaging features of CAA, apolipoprotein (APOE), and cerebrospinal fluid amyloid β (Aβ) 40 levels were studied in subjects with Down syndrome (DS, n = 117), autosomal-dominant AD (ADAD, n = 29), sporadic EOAD (n = 42), and healthy controls (n = 68).

RESULTS: CAA was present in 31%, 38%, and 12% of cognitively impaired DS, symptomatic ADAD, and sporadic EOAD subjects and in 13% and 4% of cognitively unimpaired DS individuals and healthy controls, respectively. APOE ε4 genotype was borderline significantly associated with CAA in sporadic EOAD (P = .06) but not with DS or ADAD. There were no differences in Aβ040 levels between groups or between subjects with and without CAA.

DISCUSSION: CAA is more frequently found in genetically determined AD than in sporadic EOAD. Cerebrospinal fluid Aβ40 levels are not a useful biomarker for CAA in AD.

PMID:28463681 | PMC:PMC5660938 | DOI:10.1016/j.jalz.2017.03.007


María Carmona-Iragui
Mircea Balasa
Bessy Benejam
Daniel Alcolea
Susana Fernández
Laura Videla
Isabel Sala
María Belén Sánchez-Saudinós
Estrella Morenas-Rodriguez
Roser Ribosa-Nogué
Ignacio Illán-Gala
Sofía Gonzalez-Ortiz
Jordi Clarimón
Frederick Schmitt
David K Powell
Beatriz Bosch
Albert Lladó
Michael S Rafii
Elizabeth Head
José Luis Molinuevo
Rafael Blesa
Sebastián Videla
Alberto Lleó
Raquel Sánchez-Valle
Juan Fortea